Immunovant

Q1 FY2027 EarningsQ1 FY27 results missed consensus estimates as clinical development for IMVT-1402 accelerated. Revenue remained at zero, in-line with expectations for a clinical-stage biotech. The GAAP net loss of $153.2M ($0.75 per share) was wider than the anticipated $131.0M loss ($0.63 per share), primarily driven by elevated R&D spending of $142.6M. However, the cash position of $797.8M remains robust, securing the runway through the potential commercial launch of IMVT-1402 in Graves' Disease.